Medicina, Volume 61, Issue 12
2025 December - 173 articles
Cover Story: This review explores bispecific T cell engagers (TCEs) for multiple myeloma. TCEs bind CD3 on T cells and a tumor antigen (e.g., BCMA) on myeloma cells, redirecting T cell cytotoxicity. The field has evolved from short-lived BiTEs requiring continuous infusion to next-generation, IgG-like antibodies (e.g., teclistamab) with extended half-lives, allowing convenient dosing. Clinical trials show high response rates (43–73%) and durable remissions in heavily pretreated patients. Key challenges include cytokine release syndrome, antigen loss, T cell exhaustion, and the immunosuppressive bone marrow niche. Future strategies involve trispecific antibodies, combination therapies, and mechanisms to overcome antigen escape. TCEs represent a major shift toward effective, immune-mediated disease control in myeloma. View this paper - Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
- You may sign up for email alerts to receive table of contents of newly released issues.
- PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.